DNAe
Develops diagnostics for serious blood infections.
Financials
Estimates*
GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 3.4m | 8.4m | 5.5m | 5.3m | 3.7m | 5.4m | 4.4m |
% growth | 10 % | 148 % | (34 %) | (4 %) | (31 %) | 48 % | (18 %) |
EBITDA | (21.0m) | (29.5m) | (35.9m) | (15.9m) | (1.2m) | (18.7m) | (36.0m) |
% EBITDA margin | (620 %) | (350 %) | (648 %) | (299 %) | (33 %) | (346 %) | (812 %) |
Profit | (23.3m) | (33.5m) | (48.4m) | (34.8m) | (29.7m) | (49.0m) | (61.4m) |
% profit margin | (687 %) | (398 %) | (875 %) | (654 %) | (811 %) | (906 %) | (1385 %) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
£25.0m | Debt | ||
N/A | Grant | ||
Total Funding | - |
Related Content
Recent News about DNAe
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.